Seattle’s Infectious Disease Research Institute, a nonprofit organization, reports positive early results from a clinical trial centering on the use of immunotherapy on COVID-19 patients. According to the organization’s CEO, Dr. Corey Casper, the results are “promising.”
Recently, showcases on local news King 5, the study’s goal is to investigate this approach on patients not yet in need of ventilator support. CEO Dr. Casper, also a clinical professor of global health at the University of Washington, becomes ever more upbeat as he believes their study is showing “promising” early-stage results, while the COVID-19 vaccine trials have him more upbeat than just a couple months ago, reports King 5.
TrialSite reported on this study back in April. The Seattle-based nonprofit partnered with a full-service Research Triangle-based contract research organization (CRO) called FHI Clinical to support full-service research capabilities for the immunotherapy trial based on the underlying intellectual property of Celularity.
The study involved Celularity, a clinical-stage therapeutics company, and its NK cell therapy that has been under study for the treatment of various hematologic cancers and solid tumors, as a potential treatment option targeting COVID-19.
Can Cell Therapy Address the Crisis
The hope is that the Celularity cell therapy (IMPACT Platform) can be a way of offering patients the immune cells that might make a difference in combating COVID-19.
In recent news, Celularity activated a clinical trial site in California following a CIRM (State of Cal) grant.
Call to Action: TrialSite will monitor this study, and upon completion, update as soon as the information is available. Sign up for the TrialSite Newsletter for updates.